Benitec Net Debt from 2010 to 2026

BNTC Stock  USD 12.12  0.47  4.03%   
Benitec Biopharma's Net Debt is decreasing over the years with slightly volatile fluctuation. Overall, Net Debt is projected to go to about -82.8 M this year. Net Debt is the total debt of Benitec Biopharma Ltd minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals
 
Net Debt  
First Reported
2014-06-30
Previous Quarter
-96.9 M
Current Value
-93.7 M
Quarterly Volatility
26.3 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Benitec Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Benitec Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 59.3 K, Interest Expense of 1.1 M or Selling General Administrative of 28.3 M, as well as many indicators such as Price To Sales Ratio of 64.14, Dividend Yield of 0.0012 or PTB Ratio of 6.36. Benitec financial statements analysis is a perfect complement when working with Benitec Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Benitec Stock
Check out the analysis of Benitec Biopharma Correlation against competitors.
Analyzing Benitec Biopharma's Net Debt over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Debt has evolved provides context for assessing Benitec Biopharma's current valuation and future prospects.

Latest Benitec Biopharma's Net Debt Growth Pattern

Below is the plot of the Net Debt of Benitec Biopharma Ltd over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Benitec Biopharma's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Benitec Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Debt10 Years Trend
Slightly volatile
   Net Debt   
       Timeline  

Benitec Net Debt Regression Statistics

Arithmetic Mean(31,129,605)
Coefficient Of Variation(96.15)
Mean Deviation22,706,977
Median(19,556,000)
Standard Deviation29,930,094
Sample Variance895.8T
Range95M
R-Value(0.55)
Mean Square Error669.2T
R-Squared0.30
Significance0.02
Slope(3,244,277)
Total Sum of Squares14333T

Benitec Net Debt History

2026-82.8 M
2025-87.2 M
2024-96.9 M
2023-50.6 M
2022-1.9 M
2021-3.3 M
2020-19.6 M

Other Fundumenentals of Benitec Biopharma

Benitec Biopharma Net Debt component correlations

1.0-0.98-0.76-0.3-0.290.181.0-0.360.12-0.46-0.20.990.99-0.43-0.75
1.0-0.98-0.75-0.32-0.290.151.0-0.340.1-0.43-0.20.990.99-0.41-0.74
-0.98-0.980.760.260.31-0.18-0.980.35-0.10.430.22-0.96-0.970.420.82
-0.76-0.750.760.060.32-0.66-0.760.75-0.590.860.2-0.8-0.80.820.82
-0.3-0.320.260.060.080.6-0.29-0.19-0.07-0.060.36-0.31-0.310.09-0.05
-0.29-0.290.310.320.08-0.16-0.290.33-0.110.190.79-0.25-0.250.510.26
0.180.15-0.18-0.660.6-0.160.18-0.690.55-0.760.00.210.21-0.64-0.53
1.01.0-0.98-0.76-0.29-0.290.18-0.360.11-0.45-0.20.990.99-0.42-0.75
-0.36-0.340.350.75-0.190.33-0.69-0.36-0.80.83-0.03-0.42-0.420.890.48
0.120.1-0.1-0.59-0.07-0.110.550.11-0.8-0.860.010.220.22-0.77-0.29
-0.46-0.430.430.86-0.060.19-0.76-0.450.83-0.860.08-0.53-0.530.830.62
-0.2-0.20.220.20.360.790.0-0.2-0.030.010.08-0.17-0.170.360.2
0.990.99-0.96-0.8-0.31-0.250.210.99-0.420.22-0.53-0.171.0-0.47-0.76
0.990.99-0.97-0.8-0.31-0.250.210.99-0.420.22-0.53-0.171.0-0.47-0.76
-0.43-0.410.420.820.090.51-0.64-0.420.89-0.770.830.36-0.47-0.470.54
-0.75-0.740.820.82-0.050.26-0.53-0.750.48-0.290.620.2-0.76-0.760.54
Click cells to compare fundamentals

About Benitec Biopharma Financial Statements

Benitec Biopharma stakeholders use historical fundamental indicators, such as Benitec Biopharma's Net Debt, to determine how well the company is positioned to perform in the future. Although Benitec Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Benitec Biopharma's assets and liabilities are reflected in the revenues and expenses on Benitec Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Benitec Biopharma Ltd. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Debt-87.2 M-82.8 M
Net Debt To EBITDA 2.67  1.35 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:
Check out the analysis of Benitec Biopharma Correlation against competitors.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Will Biotechnology sector continue expanding? Could Benitec diversify its offerings? Factors like these will boost the valuation of Benitec Biopharma. Projected growth potential of Benitec fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Benitec Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.09)
Revenue Per Share
0.003
Quarterly Revenue Growth
0.125
Return On Assets
(0.35)
Return On Equity
(0.53)
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Benitec Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Benitec Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Benitec Biopharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.